Previous Article | Next Article ![]()
Journal of Virology, November 1999, p. 9642-9649, Vol. 73, No. 11
Center for Retrovirus Research and Department
of Veterinary Biosciences1 and
Comprehensive Cancer Center, The Arthur James Cancer
Hospital and Research Institute,3 The Ohio State
University, Columbus, Ohio 43210, and Departments of
Medicine, Pathology, and Molecular Microbiology, Washington
University School of Medicine, St. Louis, Missouri
631102
Received 26 April 1999/Accepted 30 July 1999
Human T-cell lymphotropic virus type 1 (HTLV-1), a complex
retrovirus, encodes a hydrophobic 12-kD protein from pX open reading frame (ORF) I that localizes to cellular endomembranes and contains four minimal SH3 binding motifs (PXXP). We have demonstrated the importance of ORF I expression in the establishment of infection and
hypothesize that p12I has a role in T-cell activation. In
this study, we tested interleukin-2 (IL-2) receptor expression,
IL-2-mediated proliferation, and Jak/Stat activation in T-cell lines
immortalized with either wild-type or ORF I mutant clones of HTLV-1.
All cell lines exhibited typical patterns of T-cell markers and
maintained mutation fidelity. No significant differences between cell
lines were observed in IL-2 receptor chain ( Human T-cell lymphotropic virus type
1 (HTLV-1) is a complex retrovirus associated with adult T-cell
leukemia/lymphoma and a variety of immune system-mediated diseases
(10, 12, 14a). The virus contains, in addition to
gag, pol and env genes, a regulatory region named pX that encodes several proteins from four open reading frames (ORFs), including Tax and Rex (4, 19, 30). Tax is a
40-kD phosphoprotein encoded by ORF IV that activates transcription from the viral promoter as well as from numerous cellular genes, including interleukin-2 (IL-2) and the IL-2 receptor (IL-2R) The pX ORF I encodes conserved 152- and 99-amino-acid hydrophobic
proteins known as p27I and p12I (18,
19). However, only p12I has been detected in
eukaryotic expression systems, in which it is localized to
endomembranes (18). Using the ACH molecular clone of HTLV-1,
we have examined the role of ORF I in viral replication (6,
29). Abrogation of ORF I expression has no detectable effects on
the ability of the virus to infect or immortalize primary cells in
vitro (6, 9, 29). In vitro, however, peripheral blood
mononuclear cells (PBMC) are cultured in the presence of mitogen and
exogenous IL-2, which may obviate the need for any activating effects
of p12I. In HeLa/Tat cells, it was shown that overexpressed
p12I associated with IL-2R HTLV-1-immortalized cells are initially IL-2 dependent but may acquire
independence from exogenous IL-2 supplementation over many months in
culture (16). This IL-2 independence corresponds with
gradual, constitutive activation of the Jak/Stat signaling proteins in
all fully transformed HTLV-1-infected T-cell lines, as well as in adult
T-cell leukemia/lymphoma cells (23, 31, 33). To test the
effects of HTLV-1 ORF I expression, we examined IL-2R expression, basal
and IL-2 responsive proliferation, and Jak/Stat activation in T-cell
lines immortalized with either wild-type or mutant molecular clones of
HTLV-1 lacking expression of ORF I.
Normal, uninfected PBMC were maintained in supplemented RPMI medium
with 15% fetal bovine serum (FBS) and 10 U of human IL-2 (hIL-2) per
ml (complete media) and were stimulated with 2 µg of
phytohemagglutinin (PHA) per ml 72 h prior to electroporation (27). PBMC were transfected using 10 µg of the HTLV-1
molecular clone ACH or ACH.p12, a construct in which a PstI
site corresponding to the splice acceptor for the third exon of ORF I
has been deleted (6, 7, 17, 29). After continuous growth for
6 months, selected cultures were expanded in the presence of 10 U of
hIL-2 per ml for 12 to 18 months (Table
1). Three lines, ACH.3, ACH.MR, and
ACH.p12.3, became senescent after 18 to 24 months in culture. Immediately prior to experiments, cell lines were assayed for production of viral p19 matrix antigen by enzyme-linked immunosorbent assay (ELISA) (Cellular Products). MT-2 cells were grown as previously described (14).
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Proliferation Response to Interleukin-2 and
Jak/Stat Activation of T Cells Immortalized by Human T-Cell
Lymphotropic Virus Type 1 Is Independent of Open Reading Frame I
Expression
![]()
ABSTRACT
Top
Abstract
Text
References
,
, or
c) expression, in IL-2-mediated proliferation, or in
IL-2-induced phosphorylated forms of Stat3, Stat5, Jak1, or Jak3. The
expression of ORF I is more likely to play a role in early HTLV-1
infection, such as in the activation of quiescent T cells in vivo.
![]()
TEXT
Top
Abstract
Text
References
chain
(22). Tax-mediated activation of cellular cytokine and immediate-early genes, as well as inhibition of cell cycle regulatory proteins such as p53 and p16, is thought to contribute to the transforming potential of the virus (14a). The ORF III gene
product, Rex, is a 27-kD phosphoprotein that regulates the cytoplasmic accumulation of unspliced and singly spliced viral mRNA and possibly cellular messages such as IL-2R
(10, 12). Much less is
known about the function of pX ORFs I and II.
and
chains
(24). We have shown ORF I expression to be critical for
optimal infectivity of the virus in a rabbit model (6) and
hypothesize that p12I influences early activation of T
cells, allowing efficient transmission of the virus.
TABLE 1.
Cell surface CD receptor expression of
HTLV-I-immortalized PBMC
To confirm the
PstI mutation in each of the ACH.p12I
cell lines, genomic DNA was harvested by affinity column separation
(QIAamp; Qiagen) and examined for the presence of HTLV-1 provirus by
PCR with a primer pair specific for the HTLV-1 pX ORF I region (6555 and 7492) (6). The amplified products were digested with
PstI, which was predicted to yield fragments of 760 and 178 bp in the wild type but not in the ACH.p12I DNA. Products
were separated in a 1.5% agarose gel and stained with ethidium bromide.
For detection of the p12I message in cell lines, total mRNA was harvested by affinity column separation (RNeasy; Qiagen) and was reverse transcribed using Moloney murine leukemia virus reverse transcription (Boehringer Mannheim). Resulting cDNA was amplified as described above using the primer pair RPX3 and IK4 (corresponding to nucleotides 5094 and 6876, respectively) which spanned the second ORF I splice junction and thus yielded a product of 232 bp, corresponding to the doubly spliced pX-Rex-ORF I transcript (6, 19). Primers that amplified a 183-bp transcript of the abl gene were used as a control (6).
Surface membrane receptor expression was determined by direct labeling
of lymphocytes with fluorescein isothiocyanate-conjugated monoclonal
antibodies against CD3 (UCHT-1; Sigma), HLA class I (W6/32; Sigma), or
HLA-DR (HK14; Sigma), or with phycoerythrin (PE)-conjugated monoclonal
antibodies against CD4 (Q4120; Sigma), CD8 (UCHT-4; Sigma), IL-2R
(Mik-
3; Pharmingen), or IL-2R
(TUGh4; Pharmingen). Expression of
IL-2R
and HTLV-1 Env was determined by labeling of lymphocytes with
unconjugated monoclonal antibodies 22722.2 (R&D Systems) or IC11
(28), respectively, and followed with PE-conjugated goat
anti-mouse immunoglobulin G polyclonal antibody (Sigma). Fluorescence
was measured using a Coulter Epics Elite flow cytometer and was
analyzed using EPICS Elite software, version 4.01 (Coulter Corp.).
Group mean channel fluorescence between ACH- and
ACH.p12I-transfected lines were statistically compared
using Student's t test.
To measure IL-2 responsiveness, cells were rested in complete RPMI medium without IL-2 overnight (approximately 16 h) prior to plating 100 µl of cells (106/ml) in duplicate wells of a 96-well plate containing varying concentrations of IL-2 (0 to 40 U/ml). Immediately after plating cells (baseline samples) or after 72 h in culture, cell proliferation was monitored by a tetrazolium dye-based assay (MTS; Promega). Data were expressed as fold increase in absorbance of 72-h samples compared to baseline samples. Group means were statistically compared using Student's t test. Endogenous secretion of IL-2 by cell lines was measured by ELISA (R&D Systems).
To monitor Jak/Stat activation, cells were rested overnight in RPMI medium containing 1% FBS prior to stimulation. Prior to harvest, cells were plated in complete RPMI medium containing 15% FBS in 6-well plates in the presence or absence of 2 nM hIL-2. After a 15-min incubation, cells were washed, pelleted, and lysed by suspension at a concentration of 2.5 × 107/ml in standard radioimmunoprecipitation assay lysis buffer on ice for 2 h. Lysates were centrifuged, and 30 µg of supernatant protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis prior to transfer to nitrocellulose membranes and probing with antibodies against Stat3 (New England Biolabs), Stat5 (C-17; Santa Cruz Biotechnology), or phosphotyrosine-specific motifs of Stat proteins (phospho-Stat5 from Upstate Biotechnology and phospho-Stat3 from New England Biolabs). Development of immunoblots was performed with a chemiluminescent detection system according to the manufacturer's protocol (New England Biolabs).
For immunoprecipitation, 100 to 300 µg of precleared protein was incubated at 4°C overnight with protein A-Sepharose beads conjugated with anti-Stat or anti-Jak polyclonal antibodies: Stat5b (C-17), Jak1 (HR-785), Jak3 (C-21) (Santa Cruz). Proteins were eluted from washed beads and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis prior to transfer and probing with antiphosphotyrosine antibody (4G10; Upstate Biotechnology). The nitrocellulose membranes were stripped and reprobed with antibodies against Stat5, Jak1, or Jak3.
To determine the effect of ORF I on IL-2R expression, IL-2-responsive
proliferation, and Stat activation, eight cell lines were developed.
Four were transfected with ACH and four with ACH.p12I. Upon
outgrowth of cells in the presence of IL-2 (approximately 6 months
posttransfection) and again immediately prior to further experiments
(approximately 18 months posttransfection), the fidelity of the
PstI
mutation in the ACH.p12I-transfected lines was examined by
PCR. Proviral sequences were amplified by PCR from genomic DNA of all
eight lines (Fig. 1). The 938-bp HTLV-1
ORF I-specific amplicons from all ACH lines were digested by
PstI, whereas the DNA fragment amplified from ACH.p12I lines failed to digest, consistent with abrogation
of the PstI site that coincides with the ORF I coding the
exon splice acceptor (Fig. 1A). Compatible with the preservation of
this mutation, the ACH.p12 lines failed to express ORF I (Fig. 1B).
HTLV-1 p19 production was measured in cell culture supernatants by
ELISA. Consistent with our previous studies, all eight lines produced abundant amounts of p19 (greater than 200 pg/ml) (6, 29).
|
The cell lines were representative of all major phenotypes of T cells,
including CD4+ and CD8+ cells, dual-positive
cells, and dual-negative populations (Table 1). Major
histocompatibility complex class I and II molecules and viral gp46 Env
were expressed in 100% of the cells of all cell lines examined, with
no significant differences in mean channel fluorescence between ACH-
and ACH.p12I-transfected lines (data not shown). IL-2R
was expressed at high levels in all HTLV-1-infected cells, in
comparison to uninfected PBMC, compatible with upregulation by HTLV-1
Tax (Fig. 2). IL-2R
and -
levels in
the infected lines were comparable to that seen on uninfected,
PHA-stimulated PBMC (Fig. 2). Levels did not vary among individual cell
lines when reexamined 8 weeks later (data not shown). There were no
significant differences in IL-2R expression levels between ACH- and
ACH.p12I-immortalized lines.
|
As expected, the IL-2-independent, HTLV-1-positive cell line MT-2 was unresponsive to IL-2 (Fig. 3). In contrast, uninfected PBMC are highly IL-2 dependent and only proliferated in the presence of IL-2. All ACH- and ACH.p12I-immortalized cell lines were intermediate in basal proliferative response compared with that of MT-2 and PBMC (Fig. 3). Five of the lines responded to increasing amounts of IL-2 with vigorous proliferation, albeit less than that seen with uninfected PBMC. In contrast, three lines (ACH.3, ACH.MR, and ACH.p12.3) failed to proliferate to a great extent even in the presence of large amounts of exogenous IL-2 and eventually ceased to proliferate in culture. There was no significant difference in proliferation rates or IL-2 responsiveness between lines immortalized with ACH versus ACH.p12I. Consistent with previous reports of HTLV-1-immortalized cell lines (16), no measurable endogenous IL-2 production could be detected from any of the lines (data not shown).
|
To determine if ablation of ORF I expression influenced IL-2 signaling, we measured basal and constitutive phosphorylation of Jak1, Jak3, Stat3, and Stat5 in ACH- and ACH.p12I-immortalized cell lines. Constitutive phosphorylation of Stat3 in the absence of IL-2 was detected in the HTLV-1-transformed MT-2 cell line but not in PHA-activated PBMC, as previously shown (23). All IL-2-dependent, HTLV-1-immortalized cell lines exhibited constitutive phosphorylation of Stat3 as well, although levels were much lower than those seen with MT-2 cells (Fig. 4A). This intermediate level of constitutive Stat3 phosphorylation is consistent with previous reports (23) and, importantly, did not differ consistently between lines immortalized with ACH versus ACH.p12I. In contrast, using a phospho-specific Stat5 antibody, no constitutive phosphorylation of Stat5 was detected in any of the IL-2-dependent, HTLV-1-immortalized cell lines or in PHA-activated PBMC (Fig. 4B). Although constitutive Stat5 phosphorylation was detected in MT-2 cells, levels were much lower relative to constitutive Stat3 phosphorylation.
|
Results obtained by immunoprecipitation were similar to those obtained by immunoblotting with the phospho-Stat5 antibody (Fig. 5A). Consistent with the above results, the HTLV-1-immortalized lines demonstrated partial basal phosphorylation of Jak3 (Fig. 5B and C). As was also expected, constitutive phosphorylation of Jak3 was strong in MT-2 and absent in uninfected PBMC. In contrast, the pattern of Jak1 phosphorylation was similar to that of Stat5, with slight constitutive activity in MT-2 but none detected in any other cell line examined. Importantly, no differences in basal phosphorylation of Jak1 or Jak3 were seen between PBMC immortalized with ACH versus ACH.p12I. IL-2-responsive phosphorylation of Jak1, Jak3, Stat3, and Stat5 was marked in all HTLV-1-immortalized cell lines, PHA-activated PBMC, and MT-2 cells examined by both immunoblotting with phospho-specific Stat antibodies and by immunoprecipitation (Fig. 4 and 5). As expected, levels of total (phosphorylated and nonphosphorylated) Jak1, Jak3, Stat3, and Stat5 remained constant before and after IL-2 stimulation (Fig. 4 and 5).
|
The recent development of infectious molecular clones of HTLV-1 has
enhanced efforts to evaluate the role of viral determinants in
infection and transformation of T cells (7, 8, 17, 34). The
availability of the ACH clone allowed our study of the role of ORF I of
HTLV-1 in the infectivity of the virus, despite an apparent
dispensability of this gene region during in vitro propagation of the
virus (6, 9, 29). This is analogous to other viral
regulatory genes, including homologous regions of HTLV-2 (5,
13) and bovine leukemia virus (32), as well as human
immunodeficiency virus nef (15). Since
experiments examining the role of ORF I in vitro have been conducted in
the presence of IL-2, we postulated that these conditions obviate the
role of ORF I in viral transcription and infectivity. In support of
this, recent studies indicate that p12I associates with the
IL-2
and
c chains (24). Furthermore, p12I has homology to bovine papillomavirus E5, which has
similar cellular distribution and activates the platelet-derived growth
factor receptor (11). However, in contrast to the studies of
p12I overexpression in Hela/Tat cells (24), we
found that the differential expression of ORF I in the immortalized
cell lines had no significant effect on surface IL-2R expression.
Presumably, high levels of IL-2R
expression in these lines, compared
to uninfected PBMC, is due to the well-documented transcriptional
effects of Tax on the IL-2R
promoter (21). A functional
role of ORF I proteins is suggested by our preliminary studies that
demonstrated the inefficient transmission of HTLV-1 to resting T cells
in limiting concentrations of IL-2 by ACH.p12I-immortalized
cell lines (2).
The presence or absence of ORF I expression in the HTLV-1-immortalized cell lines used here had no apparent effects on basal or IL-2-responsive proliferation or signaling through the Jak/Stat pathway. All lines were consistent with an HTLV-1-immortalized population that is IL-2 dependent for continued proliferation but displaying some characteristics of partial IL-2 independence, including maintenance of viability and partial Jak3/Stat3 phosphorylation in the absence of IL-2. These characteristics were present in all HTLV-1-immortalized cell lines examined, regardless of the expression of ORF I, suggesting that ORF I gene products p12I and/or p27I do not greatly influence the progression of infected cells to this stage of immortalization. ORF I may be required for IL-2-independent transformation of HTLV-1-infected cells; however, this possibility seems remote since viral gene expression is not required for maintenance of the fully transformed phenotype (20). Nevertheless, it is intriguing that HTLV-1- but not HTLV-2-transformed lines consistently demonstrate constitutive activation of the Jak/Stat pathway, and the possibility that gene products unique to HTLV-1, such as p12I, are involved in this phenotype must be considered (23, 25).
We cannot rule out the use of cryptic splice sites to generate messages
with p12I coding potential or the production of
p12I from unspliced or singly spliced polycistronic
messages for viral structural proteins, although no internal ribosomal
entry sites have been described for HTLV-1. The conclusive detection of
p12I in virally infected cells is dependent upon the
generation of antibody reagents that recognize native p12I.
Attempts to produce such reagents have not been successful due to the
high hydrophobicity and poor immunogenicity of p12I
(3, 19). Nevertheless, it is important to note that the
p12I mutation used in this study is the same one that
has previously been shown to reduce viral infectivity in vivo
(6).
In summary, we demonstrate in this paper that ORF I expression does not overtly affect IL-2R expression or IL-2-mediated events during the late stages of HTLV-1-induced immortalization of infected cells. Furthermore, the early stages of acquisition of IL-2 independence do not require ORF I expression. The possibility exists that p12I/p27I are differentially expressed during the viral life cycle, as has been shown for human immunodeficiency virus Nef (1). Although ORF I transcripts were detected in the wild-type HTLV-1-immortalized cells, translational regulation may alter p12I/p27I expression at this stage of immortalization. Interestingly, p12I contains four minimal SH3 binding motifs (i.e., PXXP), which are common features of signal transduction molecules that modulate the Ras/mitogen-activated protein kinase and PI3-K signaling pathways (26). The function of ORF I genes may only be apparent during early events of viral replication, such as entry, uncoating, or integration. It therefore remains a possibility that ORF I expression modulates T-cell signaling at early stages of infection or in conditions of limited IL-2 concentrations more typical of the in vivo infection.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported, in part, by Public Health Service grants RR-14324, CA-55185, CA-16058, and CA-70259. M. D. Lairmore is supported by an Independent Scientist Career Award from the National Institutes of Health, AI-01474. B. Albrecht is supported by a fellowship from the Boehringer Ingelheim Corporation.
We thank Tim Vojt for preparation of figures and Richard K. Meister in the Center for Retrovirus Research Cytometry Laboratory for assistance with flow cytometric analysis.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Veterinary Biosciences, The Ohio State University, 1925 Coffey Rd., Columbus, OH 43210-1093. Phone: (614) 292-4819. Fax: (614) 292-6473. E-mail: lairmore.1{at}osu.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ahmad, N.,
R. K. Maitra, and S. Venkatesan.
1989.
Rev-induced modulation of Nef protein underlies temporal regulation of human immunodeficiency virus replication.
Proc. Natl. Acad. Sci. USA
86:6111-6115 |
| 2. | Albrecht, B., W. Ding, N. Collins, X. Wu, K. M. Coggeshall, P. L. Green, and M. D. Lairmore. 1999. Functional analysis of human T-cell lymphotropic virus type 1 p12 in vitro, abstr. 281, p. 281. In Abstracts of Retrovirus Meeting 1999. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. |
| 3. | Cereseto, A., Z. Berneman, I. Koralnik, J. Vaughn, G. Franchini, and M. E. Klotman. 1997. Differential expression of alternatively spliced pX mRNAs in HTLV-I-infected cell lines. Leukemia 11:866-870[Medline]. |
| 4. |
Ciminale, V.,
G. N. Pavlakis,
D. Derse,
C. P. Cunningham, and B. K. Felber.
1992.
Complex splicing in the human T-cell leukemia virus (HTLV) family of retroviruses: novel mRNAs and proteins produced by HTLV type I.
J. Virol.
66:1737-1745 |
| 5. |
Cockerell, G. L.,
J. Rovnak,
P. L. Green, and I. S. Y. Chen.
1996.
A deletion in the proximal untranslated pX region of human T-cell leukemia virus type II decreases viral replication but not infectivity in vivo.
Blood
87:1030-1035 |
| 6. |
Collins, N. D.,
G. C. Newbound,
B. Albrecht,
J. L. Beard,
L. Ratner, and M. D. Lairmore.
1998.
Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo.
Blood
91:4701-4707 |
| 7. |
Collins, N. D.,
G. C. Newbound,
L. Ratner, and M. D. Lairmore.
1996.
In vitro CD4+ lymphocyte transformation and infection in a rabbit model with a molecular clone of human T-cell lymphotropic virus type 1.
J. Virol.
70:7241-7246 |
| 8. | Derse, D., J. Mikovits, M. Polianova, B. K. Felber, and F. Ruscetti. 1995. Virions released from cells transfected with a molecular clone of human T-cell leukemia virus type I give rise to primary and secondary infections of T cells. J. Virol. 69:1907-1912[Abstract]. |
| 9. | Derse, D., J. Mikovits, and F. Ruscetti. 1997. X-I and X-II open reading frames of HTLV-I are not required for virus replication or for immortalization of primary T-cells in vitro. Virology 237:123-128[Medline]. |
| 10. |
Franchini, G.
1995.
Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection.
Blood
86:3619-3639 |
| 11. |
Franchini, G.,
J. C. Mulloy,
I. J. Koralnik,
A. Lo Monico,
J. J. Sparkowski,
T. Andresson,
D. J. Goldstein, and R. Schlegel.
1993.
The human T-cell leukemia/lymphotropic virus type I p12I protein cooperates with the E5 oncoprotein of bovine papillomavirus in cell transformation and binds the 16-kilodalton subunit of the vacuolar H+ ATPase.
J. Virol.
67:7701-7704 |
| 12. | Green, P. L., and I. S. Y. Chen. 1994. Molecular features of the human T-cell leukemia virus: mechanisms of transformation and leukemogenicity. In J. A. Levy (ed.), The Retroviridae, vol. 3. Plenum Press, New York, N.Y. |
| 13. | Green, P. L., T. M. Ross, I. S. Y. Chen, and S. Pettiford. 1995. Human T-cell leukemia virus type II nucleotide sequences between env and the last exon of tax/rex are not required for viral replication or cellular transformation. J. Virol. 69:387-394[Abstract]. |
| 14. | Guyot, D. J., G. C. Newbound, and M. D. Lairmore. 1997. Signaling via the CD2 receptor enhances HTLV-1 replication in T lymphocytes. Virology 234:123-129[Medline]. |
| 14a. |
Höllsberg, P.
1999.
Mechanisms of T-cell activation by human T-cell lymphotropic virus type 1.
Microbiol. Mol. Biol. Rev.
63:308-333 |
| 15. | Kestler, H. W., D. J. Ringler, K. Mori, D. L. Panicali, P. K. Sehgal, M. D. Daniel, and R. C. Desrosiers. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651-662[Medline]. |
| 16. |
Kimata, J. T., and L. Ratner.
1991.
Temporal regulation of viral and cellular gene expression during human T-lymphocyte type 1-mediated lymphocyte immortalization.
J. Virol.
65:4398-4407 |
| 17. | Kimata, J. T., F. Wong, J. Wang, and L. Ratner. 1994. Construction and characterization of infectious human T-cell leukemia virus type 1 molecular clones. Virology 204:656-664[Medline]. |
| 18. |
Koralnik, I. J.,
J. Fullen, and G. Franchini.
1993.
The p12, p13, and p30 proteins encoded by human T-cell leukemia/lymphotropic virus type-1 open reading frames I and II are localized in three different cellular compartments.
J. Virol.
67:2360-2366 |
| 19. |
Koralnik, I. J.,
A. Gessain,
M. E. Klotman,
A. Lo Monico,
Z. N. Berneman, and G. Franchini.
1992.
Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type 1.
Proc. Natl. Acad. Sci. USA
89:8813-8817 |
| 20. |
Korber, B.,
A. Okayama,
R. Donnelly,
N. Tachibana, and M. Essex.
1991.
Polymerase chain reaction analysis of defective human T-cell leukemia virus type 1 proviral genomes in leukemic cells of patients with adult T-cell leukemia.
J. Virol.
65:5471-5476 |
| 21. | Leung, K., and G. J. Nabel. 1988. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature 333:776-778[Medline]. |
| 22. | Mesnard, J.-M., and C. Devaux. 1999. Multiple control levels of cell proliferation by human T-cell leukemia virus type 1 Tax protein. Virology 257:277-284[Medline]. |
| 23. |
Migone, T. S.,
J. X. Lin,
A. Cereseto,
J. C. Mulloy,
J. J. Oshea,
G. Franchini, and W. J. Leonard.
1995.
Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.
Science
269:79-81 |
| 24. |
Mulloy, J. C.,
R. W. Crowley,
J. Fullen,
W. J. Leonard, and G. Franchini.
1996.
The human T-cell leukemia/lymphotropic virus type 1 p12I protein binds the interleukin-2 receptor and c chains and affects their expression on the cell surface.
J. Virol.
70:3599-3605[Abstract].
|
| 25. |
Mulloy, J. C.,
T. S. Migone,
T. M. Ross,
N. Ton,
P. L. Green,
W. J. Leonard, and G. Franchini.
1998.
Human and simian T-cell leukemia viruses type 2 (HTLV-2 and STLV-2pan-p) transform T cells independently of Jak/STAT activation.
J. Virol.
72:4408-4412 |
| 26. | Nelson, B. H., and D. M. Willerford. 1998. Biology of the interleukin-2 receptor. Adv. Immunol. 70:1-81[Medline]. |
| 27. | Newbound, G. C., J. M. Andrews, J. P. O'Rourke, J. N. Brady, and M. D. Lairmore. 1996. Human T-cell lymphotropic virus type 1 Tax mediates enhanced transcription in CD4+ T lymphocytes. J. Virol. 70:2101-2106[Abstract]. |
| 28. | Palker, T., M. Tanner, R. Scearce, R. Streilen, M. Clark, and B. Haynes. 1989. Mapping of immunogenic regions of human T-cell leukemia virus type 1 (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. J. Immunol. 142:971-978[Abstract]. |
| 29. |
Robek, M. D.,
F. H. Wong, and L. Ratner.
1998.
Human T-cell leukemia virus type 1 pX-I and pX-II open reading frames are dispensable for the immortalization of primary lymphocytes.
J. Virol.
72:4458-4462 |
| 30. |
Seiki, M.,
S. Hattori,
Y. Hirayama, and M. Yoshida.
1983.
Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA.
Proc. Natl. Acad. Sci. USA
80:3618-3622 |
| 31. |
Takemoto, S.,
J. C. Mulloy,
A. Cereseto,
T. S. Migone,
B. K. Patel,
M. Matsuoka,
K. Yamaguchi,
K. Takatsuki,
S. Kamihira,
J. D. White,
W. J. Leonard,
T. Waldmann, and G. Franchini.
1997.
Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins.
Proc. Natl. Acad. Sci. USA
94:13897-13902 |
| 32. |
Willems, L.,
P. Kerkhofs,
F. Dequiedt,
D. Portetelle,
M. Mammerickx,
A. Burny, and R. Kettmann.
1994.
Attenuation of bovine leukemia virus by deletion of R3 and G4 open reading frames.
Proc. Natl. Acad. Sci. USA
91:11532-11536 |
| 33. | Xu, X., S. H. Kang, O. Heidenreich, M. Okerholm, J. J. O'Shea, and M. I. Nerenberg. 1995. Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells. J. Clin. Investig. 96:1548-1555. |
| 34. | Zhao, T. M., M. A. Robinson, F. S. Bowers, and T. J. Kindt. 1995. Characterization of an infectious molecular clone of human T-cell leukemia virus type I. J. Virol. 69:2024-2030[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»